Navigation Links
Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKline's Avandia Increases Nine-Fold Following Publication of Meta-Analysis
Date:4/22/2008

Nearly Three-Quarters of Physicians Have Switched Patients to Merck's

Januvia, According to a New Report from Decision Resources

WALTHAM, Mass., April 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the percentage of primary care physicians (PCPs) and endocrinologists who consider the cardiovascular safety of GlaxoSmithKline's Avandia to be a major concern increased more than nine-fold following publication of a meta-analysis. Published in May 2007 by Steve Nissen in the New England Journal of Medicine, the meta-analysis calls into question the cardiovascular safety of Avandia and features analysis of data from several different trials showing that the drug increases the risk of myocardial infarction by 43 percent. Prescriptions for Avandia dropped significantly in the weeks following publication of the meta-analysis. According to the new Physician and Payer Forum report entitled Avandia One Year Later-A Physician and Payer Perspective, the full impact of the meta-analysis on Avandia prescribing has not yet been felt. 58 percent of PCPs and 52 percent of endocrinologists say they will reduce their prescribing of Avandia over the next year.

The report also finds that nearly three-quarters of physicians say they have switched patients to Merck's Januvia as a result of the Avandia meta-analysis. More than 80 percent of surveyed physicians say they will increase the number of total prescriptions they write for Januvia over the next two years. Although clinicians and managed care organizations surveyed consider metformin (Bristol-Myers Squibb's Glucophage, generics) to offer the best overall safety and efficacy, Januvia received the second greatest number of votes for "agent with the best overall safety profile" and for "lowest risk of hypoglycemia." In comparison, Amylin/Eli Lilly's Byetta was chosen by endocrinologists and MCOs as the agent least likely to cause weight gain, and the drug also received the third greatest number of votes for "agent with the best overall efficacy profile."

"Cardiovascular safety concerns have significantly impacted prescriptions for Avandia and created opportunities for other antidiabetic agents," said Donny Wong, Ph.D., principal analyst at Decision Resources. "Nearly three-quarters of physicians say they have switched patients to Januvia as a result of the Avandia meta-analysis, and one-third of PCPs and endocrinologists say they have switched patients to Byetta following publication of the Avandia meta-analysis. Nevertheless, Takeda's Actos will continue to be the market share leader among oral antidiabetic agents until the drug loses patent protection in 2011."

Avandia One Year Later-A Physician and Payer Perspective is based on a U.S. survey of 74 PCPs, 70 endocrinologists and 20 managed care pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic, and scientific factors.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources (http://www.DecisionResources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Wal-Mart & Nalgene Removing Toxic Bottles, Place Consumers Concerns First
2. 18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns
3. Operating Room Nurses are Concerned about Complications Associated with Powdered Gloves
4. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
5. Iomai Reports Going Concern Qualification in 10-K
6. CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders Equity
7. Talent Shortage Emerges as No. 1 Employer Concern: Deloitte/ISCEBS
8. National Religious Coalition Deeply Concerned by HHS Secretarys Disregard for Womens Reproductive Health
9. Project Concern International Receives a US$1 Million Grant From the Starbucks Foundations Ethos Water Fund to Provide Safe Water and Sanitation Services in Tanzania
10. Bi-Partisan Members of United States Senate Formally Raise Concerns About Proposed Cuts to Medicares Home Oxygen Benefit
11. TransUnion Addresses Ohio Attorney Generals Concerns Surrounding Non-Profit Tax-Exempt Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 23, 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, dentist ... Throughout the month of February, patients who visit Hamlin Dental Group will receive a ... for two at the Cheesecake Factory. , Tickets are available for routine dental ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... on “Doping in Sport: How the Culture Might Change,” in conjunction ... The symposium will be held at Pepperdine University in Malibu, California. , Sir ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... in clinical trials, today announced that Premier Research, a leading clinical development service ... Clinical trials are becoming increasingly complex, due in part to an array of ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for Autism ... Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly ... (ASD) to see films in an environment that accommodates their unique needs. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal ... program today with a new Indiegogo campaign . Individuals are now able ... in the Los Angeles area, either as a participating patient or through an Indiegogo ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , 23. Februar 2017 Im Rahmen ... nationale Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, 2017 mit ... einer Innovationsplattform aktiv an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. ... Continue Reading ... ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
(Date:2/23/2017)... ... Research and Markets has announced the addition of the "Global ... report to their offering. The Global Antifungal Drugs Market ... next decade to reach approximately $12.8 billion by 2025. ... the given segments on global as well as regional levels presented in ...
Breaking Medicine Technology: